Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Attributable risk

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Attributable risk. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2021-002857-28 Sponsor Protocol Number: C4671002 Start Date*: 2021-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI...
    Medical condition: Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002895-38 Sponsor Protocol Number: C4671005 Start Date*: 2021-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI...
    Medical condition: Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-001086-34 Sponsor Protocol Number: IGG-PRINTO-001 Start Date*: 2005-10-21
    Sponsor Name:Istituto Giannina Gaslini-PRINTO
    Full Title: A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los ...
    Medical condition: The present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 month...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023779-24 Sponsor Protocol Number: M10-1028 Start Date*: 2010-12-06
    Sponsor Name:Stichting Toegepast Caridologisch Onderzoek
    Full Title: A Comparison of Drug Eluting and Bare Metal Stents with Bivalirudin during PCI or Bivalirudin for 4 hours in Acute Coronary Syndromes. The Eindhoven Reperfusion Study
    Medical condition: Patients with ACS who are scheduled for primary PCI (STEMI) or for immediate PCI < 2.5 hours or early PCI < 48 hours (NSTEMI) and who are pre-treated with HLD clopidogrel
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003367-26 Sponsor Protocol Number: MK4482-001 Start Date*: 2020-11-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000969-37 Sponsor Protocol Number: AN-SCD1121 Start Date*: 2007-10-05
    Sponsor Name:Anthera Pharmaceuticals Incorporated
    Full Title: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk ...
    Medical condition: Acute Chest Syndrome (ACS) in At-Risk patients with Sickle Cell Disease (SCD) and Vaso-occlusive Crisis (VOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051895 Acute chest syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003368-24 Sponsor Protocol Number: MK-4482-002 Start Date*: 2020-11-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002569-32 Sponsor Protocol Number: izoz/0025 Start Date*: 2015-06-12
    Sponsor Name:Academic Medical Center
    Full Title: Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project
    Medical condition: prevention of HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000075-39 Sponsor Protocol Number: C4671026 Start Date*: 2022-04-05
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITAL...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2013-003956-18 Sponsor Protocol Number: PREVENT-JIA Start Date*: 2014-04-29
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA)
    Medical condition: juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10059177 Juvenile arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002447-22 Sponsor Protocol Number: C4671031 Start Date*: 2022-11-21
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004070-34 Sponsor Protocol Number: PRECAVE Start Date*: 2018-01-29
    Sponsor Name:Servicio de Urología. Hospital Universitario La Paz
    Full Title: RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE URO...
    Medical condition: Non-muscle-invasive urothelial carcinoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002132-25 Sponsor Protocol Number: 12-181 Start Date*: 2015-06-29
    Sponsor Name:University Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty
    Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial
    Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005708-13 Sponsor Protocol Number: MICENAS-2011 Start Date*: 2013-07-17
    Sponsor Name:Fundación para la Investigación Biomedica del Hospital 12 de Octubre
    Full Title: An open-label, randomized, parallel-group, multicenter, non-inferiority trial comparing the effectiveness and safety of an immuno-guided strategy versus a viremia-guided strategy for the prevention...
    Medical condition: Prophylaxis of cytomegalovirus infection in seropositive kidney transplant recipients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000582-47 Sponsor Protocol Number: CLL2-BCG Start Date*: 2015-04-15
    Sponsor Name:University of Cologne
    Full Title: A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed ...
    Medical condition: Fit and unfit patients with relapsed/refractory CLL requiring Treatment (including relapsed/refractory patients enrolled before the second amendment and relapsed high-risk patients recruited after...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004360-26 Sponsor Protocol Number: CLL16 Start Date*: 2021-08-24
    Sponsor Name:German CLL Study Group (University of Cologne)
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006439-12 Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 Start Date*: 2009-05-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: Strategic Timing of AntiRetroviral Treatment(START)
    Medical condition: HIV Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-002373-56 Sponsor Protocol Number: Start Date*: 2012-10-02
    Sponsor Name:Medical Research Council
    Full Title: PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054925 Prophylaxis against HIV infection PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002827-36 Sponsor Protocol Number: C4671042 Start Date*: 2023-02-10
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS A...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004337-17 Sponsor Protocol Number: HO159 Start Date*: 2020-07-23
    Sponsor Name:HOVON Foundation
    Full Title: REtreatment with VEnetoclax and Acalabrutinib after venetoclax Limited duration (REVEAL) A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed a...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:44:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA